The novel treatment did not meet primary endpoints, however it did reduce hospitalization, adverse outcomes, and death.

REVERSE-AD is an ongoing phase 3 cohort study evaluating the reversal effects of idarucizumab on dabigatran.

Treatment with IV tPA appeared safe and feasible with stroke onset confirmation from MRI.

Improvements in Rankin Scale score, Stroke Impact Scale-16, and Montreal Cognitive Assessment were observed in the treatment group.

Those who slept more than 8 hours had a 146% greater risk of stroke.

Patients taking pioglitazone saw a 24% reduction in risk for recurrent stroke or myocardial infarction compared to placebo.

The risk among people with migraine with aura was especially high for cardioembolic stroke.

Surprisingly, multiple types of stroke were associated with a greater risk of seizure than TBI.

The authors speculate that women may have pre-stroke functional deficits, and minorities may have poorer access to care.

Over 20% of women currently on HRT saw an increase in migraine severity.

The guidelines recommend that physicians be specially trained in endovascular neurosurgery in order to perform the procedure.

All is not lost for patients presenting with severe stroke beyond the 6-hour mark.

Time to treatment for ischemic stroke is critical and directly affects functional outcomes.

The long-term benefits of endovascular thrombectomy appear to offset the costs of the procedure.